The use of high-efficiency particulate air-filter respirators to protect hospital workers from tuberculosis. A cost-effectiveness analysis.

BACKGROUND After outbreaks of multidrug-resistant tuberculosis, the Centers for Disease Control and Prevention proposed the use of respirators with high-efficiency particulate air filters (HEPA respirators) as part of isolation precautions against tuberculosis, along with a respiratory-protection program for health care workers that includes medical evaluation, training, and tests of the fit of the respirators. Each HEPA respirator costs between $7.51 and $9.08, about 10 times the cost of respirators currently used. METHODS We conducted a cost-effectiveness analysis using data from the University of Virginia Hospital on exposure to patients with tuberculosis and rates at which the purified-protein-derivative (PPD) skin test became positive in hospital workers. The costs of a respiratory-protection program were based on those of an existing program for workers dealing with hazardous substances. RESULTS During 1992, 11 patients with documented tuberculosis were admitted to our hospital. Eight of 3852 workers (0.2 percent) had PPD tests that became positive. Five of these conversions were believed to be due to the booster phenomenon; one followed unprotected exposure to a patient not yet in isolation; the other two occurred in workers who had never entered a tuberculosis isolation room. These data suggest that it will take more than one year for the use of HEPA respirators to prevent a single conversion of the PPD test. Assuming that one conversion is prevented per year, however, it would take 41 years at out hospital to prevent one case of occupationally acquired tuberculosis, at a cost of $1.3 million to $18.5 million. CONCLUSIONS Given the effectiveness of currently recommended measures to prevent nosocomial transmission of tuberculosis, the addition of HEPA respirators would offer negligible protective efficacy at great cost.

[1]  M. Fischl,et al.  An Outbreak of Tuberculosis Caused by Multiple-Drug-resistant Tubercle Bacilli among Patients with HIV Infection , 1992, Annals of Internal Medicine.

[2]  Susan Z. Barrows,et al.  Tuberculosis in the 1990s , 1993, Annals of Internal Medicine.

[3]  Iuat Efficacy of various duration of isoniazid preventive therapy for tuberculosis : five years follow-up in the IUAT trial , 1982 .

[4]  H S Kantor,et al.  Nosocomial transmission of tuberculosis from unsuspected disease. , 1988, The American journal of medicine.

[5]  D. Snider,et al.  Multidrug-resistant Tuberculosis , 1992, Annals of Internal Medicine.

[6]  T. Frieden,et al.  The emergence of drug-resistant tuberculosis in New York City. , 1993, The New England journal of medicine.

[7]  A K Highsmith,et al.  Surveillance for waterborne disease outbreaks--United States, 1991-1992. , 1993, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[8]  R. Wenzel,et al.  Minimizing tuberculosis risk to hospital personnel and students exposed to unsuspected disease. , 1975, Annals of internal medicine.

[9]  S. Oldham,et al.  Clinical Presentation and Outcome of Patients with HIV Infection and Tuberculosis Caused by Multiple-Drug-resistant Bacilli , 1992, Annals of Internal Medicine.

[10]  R. Haley,et al.  Tuberculosis epidemic among hospital personnel. , 1989 .

[11]  J. Weissler Tuberculosis--immunopathogenesis and therapy. , 1993, The American journal of the medical sciences.

[12]  J. T. Crawford,et al.  An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. , 1992, The New England journal of medicine.

[13]  W. M. Ewing,et al.  Nosocomial transmission of tuberculosis associated with a draining abscess. , 1990, The Journal of infectious diseases.

[14]  L G Escobedo,et al.  Behavioral Risk Factor Surveillance, 1988. , 1990, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[15]  L. Ackerson,et al.  Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. , 1993, The New England journal of medicine.

[16]  J. T. Crawford,et al.  Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers. , 1992, Annals of internal medicine.

[17]  L. Riley Drug-resistant tuberculosis. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.